As cDC1s have been previously shown to produce Cxcr3 ligands in subcutaneous tumor models [13], we posited that the Cxcr3 pathway may play a role in tumor-specific T cell fate during pancreatic cancer growth and immunotherapy. The gene discussed is CXCR3; the disease is neoplasm.